Nephrotoxicity of the BRAF-kinase inhibitor Vemurafenib isdriven by off-target Ferrochelatase inhibition
Y. Bai, J. Y. Kim, L. A. Jayne, M. Gandhi, K. M. Huang, J. A. Silvaroli, V. Sander, J. Prosek, K. D. Jhaveri, S. D. Baker, A. Sparreboom, A. Bajwa, N. S. Pabla
This study identifies off-target ferrochelatase inhibition as a mechanism of vemurafenib-induced nephrotoxicity in renal tubular epithelial cells.
bioRxiv · Jan 29, 2021 · PreprintPharmacology & Toxicology